Resolution of endothelial activation and down-regulation of Tie2 receptor in psoriatic skin after infliximab therapy

Journal of the American Academy of Dermatology

Volumn 54, Issue 6, 2006, Pages 1003-1012

  Markham, Trevor ^a   Mullan, Ronan ^a   Golden Mason, Lucy ^c   Rogers, Sarah ^b   Bresnihan, Barry ^a   FitzGerald, Oliver ^a   Fearon, Ursula ^a   Veale, Douglas J ^a  

^a Departments of Rheumatology   (Ireland)

^b Dermatology

^c ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; CD31 ANTIGEN; CELL ADHESION MOLECULE; CYCLOSPORIN; INFLIXIMAB; MESSENGER RNA; METHOTREXATE; PREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ADULT; ARTICLE; BODY SURFACE; CELL ACTIVATION; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE SEVERITY; DOWN REGULATION; ENDOTHELIUM; FEMALE; HOSPITALIZATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOLOGY; INFLAMMATORY INFILTRATE; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS; PSORIATIC ARTHRITIS; QUESTIONNAIRE; REAL TIME POLYMERASE CHAIN REACTION; RESPIRATORY TRACT INFECTION; SCORING SYSTEM; SKIN BIOPSY; STATISTICAL SIGNIFICANCE;

ADULT; ANTIBODIES, MONOCLONAL; DOWN-REGULATION; ENDOTHELIUM; FEMALE; HUMANS; MALE; MIDDLE AGED; PSORIASIS; RECEPTOR, TIE-2; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33646510771     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2006.01.038     Document Type: Article

References (50)

1. Koo J. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin 14 (1996) 485-496
2. Ortonne J.P. Recent developments in the understanding of the pathogenesis of psoriasis. Br J Dermatol 140 Suppl (1999) 1-7
3. Wakefield P.E., James W.D., Samlaska C.P., and Meltzer M.S. Tumor necrosis factor. J Am Acad Dermatol 24 (1991) 675-685
4. Paleolog E.M., Young S., Stark A.C., McCloskey R.V., Feldmann M., and Maini R.N. Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis. Arthritis Rheum 41 (1998) 1258-1265
5. Braverman I.M., and Yen A. Microcirculation in psoriatic skin. J Invest Dermatol 62 (1974) 493-502
6. Braverman I.M., and Yen A. Ultrastructure of the capillary loops in the dermal papillae of psoriasis. J Invest Dermatol 68 (1977) 53-60
7. Hull S.M., Goodfield M., Wood E.J., and Cunliffe W.J. Active and inactive edges of psoriatic plaques: identification by tracing and investigation by laser-Doppler flowmetry and immunocytochemical techniques. J Invest Dermatol 92 (1989) 782-785
8. Brooks P.C., Clark R.A., and Cheresh D.A. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 264 (1994) 569-571
9. Creamer D., Allen M., Sousa A., Poston R., and Barker J. Altered vascular endothelium integrin expression in psoriasis. Am J Pathol 147 (1995) 1661-1667
10. Nickoloff B.J., Mitra R.S., Varani J., Dixit V.M., and Polverini P.J. Aberrant production of interleukin-8 and thrombospondin-1 by psoriatic keratinocytes mediates angiogenesis. Am J Pathol 144 (1994) 820-828
11. Detmar M., Brown L.F., Claffey K.P., Yeo K.T., Kocher O., Jackman R.W., et al. Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med 180 (1994) 1141-1146
12. Ballaun C., Weninger W., Uthman A., Weich H., and Tschachler E. Human keratinocytes express the three major splice forms of vascular endothelial growth factor. J Invest Dermatol 104 (1995) 7-10
13. Cines D.B., Pollak E.S., Buck C.A., Loscalzo J., Zimmerman G.A., McEver R.P., et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 91 (1998) 3527-3561
14. Suri C., Jones P.F., Patan S., Bartunkova S., Maisonpierre P.C., Davis S., et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 87 (1996) 1171-1180
15. Holash J., Maisonpierre P.C., Compton D., Boland P., Alexander C.R., Zagzag D., et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284 (1999) 1994-1998
16. Kuroda K., Sapadin A., Shoji T., Fleischmajer R., and Lebwohl M. Altered expression of angiopoietins and Tie2 endothelium receptor in psoriasis. J Invest Dermatol 116 (2001) 713-720
17. DeBusk L.M., Chen Y., Nishishita T., Chen J., Thomas J.W., and Lin P.C. Tie2 receptor tyrosine kinase, a major mediator of tumor necrosis factor alpha-induced angiogenesis in rheumatoid arthritis. Arthritis Rheum 48 (2003) 2461-2471
18. Chen J.X., Chen Y., DeBusk L., Lin W., and Lin P.C. Dual functional roles of Tie-2/angiopoietin in TNF-alpha-mediated angiogenesis. Am J Physiol Heart Circ Physiol 287 (2004) H187-H195
19. Mease P.J., Goffe B.S., Metz J., VanderStoep A., Finck B., and Burge D.J. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial. Lancet 356 (2000) 385-390
20. Gottlieb A.B., Matheson R.T., Lowe N., Krueger G.G., Kang S., Goffe B.S., et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 139 (2003) 1627-1632
21. Oh C.J., Das K.M., and Gottlieb A.B. Treatment with anti-tumor necrosis factor alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. J Am Acad Dermatol 42 (2000) 829-830
22. Tan M.H., Gordon M., Lebwohl O., George J., and Lebwohl M.G. Improvement of pyoderma gangrenosum and psoriasis associated with Crohn disease with anti-tumor necrosis factor alpha monoclonal antibody. Arch Dermatol 137 (2001) 930-933
23. Ogilvie A.L., Antoni C., Dechant C., Manger B., Kalden J.R., Schuler G., and Luftl M. Treatment of psoriatic arthritis with antitumor necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate. Br J Dermatol 144 (2001) 587-589
24. Chaudhari U., Romano P., Mulcahy L.D., Dooley L.T., Baker D.G., and Gottlieb A.B. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomized trial. Lancet 357 (2001) 1842-1847
25. Wollina U., and Konrad H. Treatment of recalcitrant psoriatic arthritis with anti-tumor necrosis factor-alpha antibody. J Eur Acad Dermatol Venereol 16 (2002) 127-129
26. Canete J.D., Pablos J.L., Sanmarti R., Mallofre C., Marsal S., Maymo J., et al. Antiangiogenic effects of anti-tumor necrosis factor alpha therapy with infliximab in psoriatic arthritis. Arthritis Rheum 50 (2004) 1636-1641
27. Tak P.P., van der Lubbe P.A., Cauli A., Daha M.R., Smeets T.J., Kluin P.M., et al. Reduction of synovial inflammation after anti-CD4 monoclonal antibody treatment in early rheumatoid arthritis. Arthritis Rheum 38 (1995) 1457-1465
28. Youssef P.P., Kraan M., Breedveld F., Bresnihan B., Cassidy N., Cunnane G., et al. Quantitative microscopic analysis of inflammation in rheumatoid arthritis synovial membrane samples selected at arthroscopy compared with samples obtained blindly by needle biopsy. Arthritis Rheum 41 (1998) 663-669
29. Shahrara S., Volin M.V., Connors M.A., Haines G.K., and Koch A.E. Differential expression of the angiogenic Tie receptor family in arthritic and normal synovial tissue. Arthritis Res 4 (2002) 201-208
30. Chang H., Wang B.W., Kuan P., and Shyu K.G. Cyclical mechanical stretch enhances angiopoietin-2 and Tie2 receptor expression in cultured human umbilical vein endothelial cells. Clin Sci (Colch) 104 (2003) 421-428
31. Stordeur P., Poulin L.F., Craciun L., Zhou L., Schandene L., de Lavareille A., et al. Cytokine mRNA quantification by real-time PCR. J Immunol Methods 259 (2002) 55-64
32. Blaschke V., Reich K., Blaschke S., Zipprich S., and Neumann C. Rapid quantitation of proinflammatory and chemoattractant cytokine expression in small tissue samples and monocyte-derived dendritic cells: validation of a new real-time RT-PCR technology. J Immunol Methods 246 (2000) 79-90
33. Veale D., Rogers S., and Fitzgerald O. Immunolocalization of adhesion molecules in psoriatic arthritis, psoriatic and normal skin. Br J Dermatol 132 (1995) 32-38
34. Schopf R.E., Aust H., and Knop J. Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor alpha, infliximab. J Am Acad Dermatol 46 (2002) 886-891
35. Gottlieb A.B., Evans R., Li S., Dooley L.T., Guzzo C.A., Baker D., et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 51 (2004) 534-542
36. Goedkoop A.Y., Kraan M.C., Picavet D.I., de Rie M.A., Teunissen M.B., Bos J.D., and Tak P.P. Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-center study. Arthritis Res Ther 6 (2004) R326-R334
37. Gottlieb A.B., Masud S., Ramamurthi R., Abdulghani A., Romano P., Chaudhari U., et al. Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-alpha monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris. J Am Acad Dermatol 48 (2003) 68-75
38. Baert F.J., D'Haens G.R., Peeters M., Hiele M.I., Schaible T.F., Shealy D., et al. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology 116 (1999) 22-28
39. Taylor P.C., Peters A.M., Paleolog E., Chapman P.T., Elliott M.J., McCloskey R., et al. Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis. Arthritis Rheum 43 (2000) 38-47
40. Tak P.P., Taylor P.C., Breedveld F.C., Smeets T.J., Daha M.R., Kluin P.M., et al. Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum 39 (1996) 1077-1081
41. Smeets T.J., Kraan M.C., van Loon M.E., and Tak P.P. Tumor necrosis factor alpha blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue. Arthritis Rheum 48 (2003) 2155-2162
42. Paleolog E.M., Hunt M., Elliott M.J., Feldmann M., Maini R.N., and Woody J.N. Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor alpha antibody in rheumatoid arthritis. Arthritis Rheum 39 (1996) 1082-1091
43. Bhushan M., McLaughlin B., Weiss J.B., and Griffiths C.E. Levels of endothelial cell stimulating angiogenesis factor and vascular endothelial growth factor are elevated in psoriasis. Br J Dermatol 141 (1999) 1054-1060
44. Creamer D., Allen M., Jaggar R., Stevens R., Bicknell R., and Barker J. Mediation of systemic vascular hyperpermeability in severe psoriasis by circulating vascular endothelial growth factor. Arch Dermatol 138 (2002) 791-796
45. Fearon U., Griosios K., Fraser A., Reece R., Emery P., Jones P.F., and Veale D.J. Angiopoietins, growth factors, and vascular morphology in early arthritis. J Rheumatol 30 (2003) 260-268
46. Veale D., Yanni G., Rogers S., Barnes L., Bresnihan B., and Fitzgerald O. Reduced synovial membrane macrophage numbers, ELAM-1 expression, and lining layer hyperplasia in psoriatic arthritis as compared with rheumatoid arthritis. Arthritis Rheum 36 (1993) 893-900
47. Gravallese E.M., Pettit A.R., Lee R., Madore R., Manning C., Tsay A., et al. Angiopoietin-1 is expressed in the synovium of patients with rheumatoid arthritis and is induced by tumor necrosis factor alpha. Ann Rheum Dis 62 (2003) 100-107
48. Kim I., Kim J.H., Ryu Y.S., Liu M., and Koh G.Y. Tumor necrosis factor-alpha upregulates angiopoietin-2 in human umbilical vein endothelial cells. Biochem Biophys Res Commun 269 (2000) 361-365
49. Voskas D., Jones N., Van Slyke P., Sturk C., Chang W., Haninec A., et al. A cyclosporine-sensitive psoriasis-like disease produced in Tie2 transgenic mice. Am J Pathol 166 (2005) 843-855
50. Keane J., Gershon S., Wise R.P., Mirabile-Levens E., Kasznica J., Schwieterman W.D., et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345 (2001) 1098-1104